In a groundbreaking study published in the New England Medical Journal, researchers observed that tirzepatide significantly reduces the risk of developing diabetes by 94% in high-risk individuals.
The Phase 3 trial highlighted that only 1.3% of participants on tirzepatide received a diabetes diagnosis after 176 weeks, compared to 13.3% of the placebo group, demonstrating tirzepatide's efficacy.
While previous research hinted at potential weight regain after stopping GLP-1 medications, this study indicated that tirzepatide’s diabetes prevention benefits seemed to persist, maintaining lower blood sugar levels.
The study involved over 2500 overweight subjects at high risk for diabetes, and through weekly injections of varying doses of tirzepatide, researchers highlighted its role in weight loss alongside diabetes prevention.
Collection
[
|
...
]